Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Intercept Pharmaceuticals (ICPT)

Intercept Pharmaceuticals (ICPT)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
19.00 +0.04 (+0.21%) 11/07/23 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 19.00 unch (unch) -
Quote Overview for Tue, Nov 7th, 2023
Day Low
18.98
Day High
19.01
Open 19.00
Previous Close 18.96 18.96
Volume 3,963,400 3,963,400
Avg Vol 1,984,495 1,984,495
Stochastic %K 93.26% 93.26%
Weighted Alpha -13.30 -13.30
5-Day Change +0.07 (+0.37%) +0.07 (+0.37%)
52-Week Range 8.82 - 21.86 8.82 - 21.86
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 793,877
  • Shares Outstanding, K 41,783
  • Annual Sales, $ 285,710 K
  • Annual Income, $ 221,820 K
  • EBIT $ -83 M
  • EBITDA $ -81 M
  • 60-Month Beta 0.88
  • Price/Sales 2.77
  • Price/Cash Flow N/A
  • Price/Book 11.05
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.37
  • Most Recent Earnings $-0.07 on 11/06/23
  • Next Earnings Date 11/07/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.02
  • Number of Estimates 8
  • High Estimate 0.36
  • Low Estimate -0.36
  • Prior Year -0.42
  • Growth Rate Est. (year over year) +95.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.01 +11.67%
on 10/13/23
Period Open: 18.60
19.02 -0.11%
on 11/06/23
+0.40 (+2.15%)
since 10/06/23
3-Month
9.70 +95.88%
on 08/14/23
Period Open: 10.39
19.02 -0.11%
on 11/06/23
+8.61 (+82.87%)
since 08/07/23
52-Week
8.82 +115.38%
on 05/24/23
Period Open: 15.32
21.86 -13.08%
on 02/08/23
+3.68 (+24.02%)
since 11/07/22

Most Recent Stories

More News
Intercept: Q3 Earnings Snapshot

Intercept: Q3 Earnings Snapshot

ICPT : 19.00 (+0.21%)
Moore Kuehn Encourages ICPT, SRT, PCTI, and SP Investors to Contact Law Firm

/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...

SRT : 4.42 (+1.14%)
ICPT : 19.00 (+0.21%)
PCTI : 6.99 (-0.14%)
SP : 53.99 (+0.04%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMTI, ICPT, FNCB

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

FNCB : 6.75 (+5.30%)
ICPT : 19.00 (+0.21%)
AMTI : 0.2630 (-14.30%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMTI, CHS, FNCB, ICPT

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

FNCB : 6.75 (+5.30%)
ICPT : 19.00 (+0.21%)
AMTI : 0.2630 (-14.30%)
CHS : 7.59 (-0.13%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SPLK, ICPT, CHS, AMTI

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

SPLK : 156.90 (+0.25%)
ICPT : 19.00 (+0.21%)
CHS : 7.59 (-0.13%)
AMTI : 0.2630 (-14.30%)
Moore Kuehn Encourages AMTI, SPLK, ICPT, and CHS Investors to Contact Law Firm

/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...

SPLK : 156.90 (+0.25%)
ICPT : 19.00 (+0.21%)
AMTI : 0.2630 (-14.30%)
CHS : 7.59 (-0.13%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ICPT, PFSW, AVTA, CATC

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

CATC : 73.59 (-0.42%)
ICPT : 19.00 (+0.21%)
AVTA : 25.99 (-0.04%)
PFSW : 7.49 (unch)
Why Intercept Pharmaceuticals Stock Is Skyrocketing Today

Intercept is on track to be acquired by Alfasigma at a significant premium compared to recent prices.

ICPT : 19.00 (+0.21%)
Shareholder Alert: Ademi LLP investigates whether Intercept Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Alfasigma

/PRNewswire/ -- Ademi LLP is investigating Intercept (Nasdaq: ICPT) for possible breaches of fiduciary duty and other violations of law in its transaction with...

ICPT : 19.00 (+0.21%)
Why CymaBay Therapeutics Stock Is Jumping Today

The momentum continues after CymaBay reported great clinical results on Thursday.

CBAY : 32.48 (+0.03%)
ICPT : 19.00 (+0.21%)
Intercept: Q2 Earnings Snapshot

Intercept: Q2 Earnings Snapshot

ICPT : 19.00 (+0.21%)
Markets Today: Stocks Extend Their Rally After U.S. Producer Prices Soften

Morning Markets September E-Mini S&P 500 futures (ESU2 3) this morning are up +0.37% at a 15-month high, and Sep Nasdaq 100 E-Mini futures (NQU2 3) are up +0.73% at a 17-month high. U.S. stock index futures...

META : 520.27 (+4.00%)
TTD : 50.08 (+2.92%)
NQM25 : 18,799.00 (-0.03%)
DAL : 41.40 (+2.63%)
COIN : 194.80 (+2.53%)
DIS : 87.29 (+1.39%)
ESM25 : 5,402.75 (+0.02%)
VSAT : 8.42 (+3.19%)
SOFI : 11.74 (+4.17%)
CVNA : 220.94 (+4.24%)
PEP : 142.26 (-0.84%)
ICPT : 19.00 (+0.21%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intercept Pharmaceuticals, Inc. - ICPT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT)....

ICPT : 19.00 (+0.21%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intercept Pharmaceuticals, Inc. - ICPT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT)....

ICPT : 19.00 (+0.21%)
Why Madrigal Pharmaceuticals Stock Is Marching Higher Today

Two key tailwinds appear to be lifting the stock today.

MDGL : 308.79 (+2.01%)
ICPT : 19.00 (+0.21%)
Markets Today: Stocks Fall as U.S. Debt Ceiling Deal Remains Elusive

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are down -0.27%, and June Nasdaq 100 E-Mini futures (NQM2 3) are down -0.31%. U.S. stock index futures this morning are moderately lower...

PACW : 7.54 (-2.71%)
RYAN : 69.42 (-0.93%)
ZM : 72.83 (+1.52%)
ESM25 : 5,402.75 (+0.02%)
LOW : 217.76 (-0.07%)
AZO : 3,652.11 (-0.72%)
YELP : 34.42 (+2.62%)
ICPT : 19.00 (+0.21%)
NQM25 : 18,799.00 (-0.03%)
DKS : 184.34 (+1.95%)
Micron, American Airlines fall; PacWest, Plug Power rise

Stocks that traded heavily or had substantial price changes Monday: Micron, American Airlines fall; PacWest, Plug Power rise

PACW : 7.54 (-2.71%)
PDCE : 73.85 (-0.27%)
CVX : 136.68 (-0.45%)
ALB : 55.64 (+1.59%)
MU : 72.93 (+3.87%)
PLUG : 0.8407 (-3.89%)
ICPT : 19.00 (+0.21%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intercept Pharmaceuticals, Inc. - ICPT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT)....

ICPT : 19.00 (+0.21%)
Why Intercept Pharmaceuticals Stock Plunged Today

A modest revenue miss sparked a sell-off in the liver disease company's shares today.

ICPT : 19.00 (+0.21%)
Intercept: Q1 Earnings Snapshot

Intercept: Q1 Earnings Snapshot

ICPT : 19.00 (+0.21%)
Intercept: Q4 Earnings Snapshot

Intercept: Q4 Earnings Snapshot

ICPT : 19.00 (+0.21%)
This Stock That Tripled in 2022 Could Rocket Even Higher in 2023

Potential suitors with heaps of cash to spend are lining up to get a closer look at this company's results.

EVR : 187.27 (+1.63%)
VKTX : 25.79 (+1.22%)
MDGL : 308.79 (+2.01%)
ICPT : 19.00 (+0.21%)
PFE : 22.39 (-0.62%)
Komodo Health’s Real-World Evidence and Technology Platform Powers Two Real-World Analyses in Primary Biliary Cholangitis for Intercept Pharmaceuticals

Today, Komodo Health announced a collaboration with Intercept Pharmaceuticals (Nasdaq: ICPT), powering clinical research and new real-world evidence with Komodo’s platform. Intercept leveraged Komodo’s...

ICPT : 19.00 (+0.21%)
Why Intercept Pharmaceuticals Stock Is Soaring Today

Investors are cheering the drugmaker's Q3 update.

ICPT : 19.00 (+0.21%)
Intercept: Q3 Earnings Snapshot

Intercept: Q3 Earnings Snapshot

ICPT : 19.00 (+0.21%)
Nike's Down, but These 2 Nasdaq Stocks Fell Even Further Friday

Poor earnings and a business setback were costly for these companies.

COMP : 7.23 (+4.03%)
$NASX : 16,708.05 (+2.50%)
RCII : 26.78 (-0.11%)
NKE : 57.39 (+0.58%)
ICPT : 19.00 (+0.21%)
Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022

MORRISTOWN, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the...

ICPT : 19.00 (+0.21%)
Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S.

MORRISTOWN, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development...

ICPT : 19.00 (+0.21%)
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions

Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in...

DNLI : 14.87 (+1.85%)
SPRC : 0.2870 (+4.52%)
SAGE : 7.62 (-0.78%)
ICPT : 19.00 (+0.21%)
SAVA : 1.6600 (+4.40%)
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions

/PRNewswire/ -- In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the development of...

DNLI : 14.87 (+1.85%)
SPRC : 0.2870 (+4.52%)
SAGE : 7.62 (-0.78%)
ICPT : 19.00 (+0.21%)
SAVA : 1.6600 (+4.40%)

Business Summary

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing novel therapeutics to treat chronic liver diseases to market. The company's focus is on treating orphan and more prevalent liver diseases with limited treatment options. The company received FDA approval for Ocaliva an...

See More

Key Turning Points

3rd Resistance Point 19.04
2nd Resistance Point 19.03
1st Resistance Point 19.01
Last Price 19.00
1st Support Level 18.98
2nd Support Level 18.97
3rd Support Level 18.95

See More

52-Week High 21.86
Last Price 19.00
Fibonacci 61.8% 16.88
Fibonacci 50% 15.34
Fibonacci 38.2% 13.80
52-Week Low 8.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.